OR
OrbiMed
Private equity / VC · Founded 1989 · Active in 2026
OrbiMed is a private equity / vc based in USA, founded in 1989. The page below shows 115 Power Law outcomes from OrbiMed's portfolio — 76 unicorns ($1B+ valuation) and 9 additional thoroughbreds (companies that crossed $100M+ in revenue without yet reaching $1B+ valuation).
Outcomes are concentrated in Biotech & Life Sciences · Health Tech & Medtech; top portfolio geographies are USA · China · Canada. OrbiMed ranks #98 in Global in the 2026 Dealroom Power Law Investor Ranking by cross-stage outcomes.
OrbiMed’s biggest exits.
OrbiMed portfolio companies worth $1B+ that have IPO’d or been acquired. Each shows its valuation at exit and, in grey, its current value if still public.
+45 more $1B+ exits on the full Dealroom profile.
The 115 OrbiMed Power Law outcomes ($100M+ revenue or $1B+ valuation).
Snapshot of where the outcomes are concentrated by country, sector, and stage entered.
-
USA89
-
China10
-
Canada5
-
UK3
-
Denmark2
-
Switzerland2
-
France1
-
Netherlands1
-
India1
-
Belgium1
-
Biotech & Life Sciences111
-
Health Tech & Medtech4
-
Series B+62
-
Series A24
-
Seed1
OrbiMed’s biggest current holdings.
An estimate of OrbiMed’s largest live positions — disclosed shareholding × Dealroom’s latest valuation — across 1 companies where OrbiMed is a named shareholder, worth about $16M in estimated equity value.
-
1
Miaoshou Doctor
0.7%
$2.3B
$16M
Estimated value = OrbiMed’s disclosed ownership % × Dealroom’s latest company valuation; direct named stakes only, exited positions excluded. Figures are indicative, not reported marks. See the underlying cap tables on Dealroom →
OrbiMed's 115 Power Law outcomes.
How does OrbiMed stack up?
OrbiMed in orange, your selection in blue and other colours. Pick from the global roster of 609 peer investors — scope by startup location or hit "Find similar shapes" to auto-pick the three closest. The funnel matrix mirrors the spider chart on the ranking page; the line chart shows each firm's share of unicorns minted in the selected startup location — peaks reveal vintage years.
Share of new unicorns per year
% of global unicorns minted that year, year by year · hover the chart to see which unicornsStage focus
Companies by selected outcome stageSector focus
Companies per investor across the 10 highest-volume sectorsBeyond Unicorns — how the portfolio compounds
% of each investor's unicorn portfolio that later crossed $10B, $25B and $50B. Pick a sort tier and entry stage.Where OrbiMed's portfolio founders come from — and where they studied.
89 founders across the 115 Power Law outcomes — split by country of origin, university attended, and the company they worked at before founding. The University of British Columbia and Stemcentrx are the deepest single pipelines.
Key people at OrbiMed.
Market sentiment
What the market is saying about OrbiMed
An AI-synthesized read of the highest-engagement posts about OrbiMed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
In the news
Latest news about OrbiMed
Recent press, funding announcements, and portfolio moves mentioning OrbiMed — pulled live from Dealroom's news feed.
Want the full picture on OrbiMed?
The Dealroom platform tracks every round, every co-investor, and every portfolio company in real time — across 25,000+ investors and 3M+ companies globally.